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Although the antiarrhythmic aspect of amiodarone has
been extensivelystudied, its effects on His-Purkinje sys-
tem conduction and refractoriness have not been sys-
tematically investigated in human beings. In 24 patients,
anterograde His-Purkinje system conduction (HV inter-
vals)and variables of His-Purkinje system refractoriness
using the ventricular extrastimulus (Vz) technique were
analyzed before and after long-term therapy with amio-
darone, The mean duration of amiodarone therapy at
the time of repeat study was 16.2 ± 7.7 weeks (range
Il to 42). The anterograde His-Purkinje system con-
duction time (HV interval) measured 49.6 ± 9.5 ms
(range 40 to 80) before and 60.6 ± 10.7 ms (range 45
to 90) after amiodarone (p < 0.005). During retrograde
refractory period studies, the longest VI Vz interval at
which a retrograde His bundle potential (Hz) emerged
from the Vz electrogram (relative refractory period of
Amiodarone is a potent antiarrhythmic agent, particularly
in its oral form (1-10). Studies of electrophysiologic effects
of amiodarone during long-term oral therapy (4,6,10) have
shown the drug to prolong refractoriness of the atrium,
ventricular myocardium, accessory pathway and the atrio-
ventricular (AV) node. Although this agent is effective in
controlling ventricular tachycardia, its electrophysiologic
actions on refractoriness of the human His-Purkinje system
have not been systematically evaluated. Paucity of data in
this regard is partly related to the drug's significant prolon-
gation of AV nodal refractoriness, which makes His-Pur-
kinje s) stem refractoriness difficult to assess during antero-
grade propagation of impulses. Because the ventricular ex-
trastimulus method circumvents these problems, this tech-
nique was employed to systematically study the refracto-
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the His-Purkinje system) was consistently longer after
amiodarone as compared with the control period (376.4
± 46.6 versus 318.8 ± 33.1 ms, p < 0.005). Similarly,
the shortest and longest His-Purkinje system conduction
times (VzHz interval) at comparable VI Vz intervals were
uniformly and significantly prolonged after administra-
tion of the drug. Amiodarone also abolished macro-
reentry in the His-Purkinje system in six of the nine
patients who showed such reentry during the control
period. The effectiverefractory period of the ventricular
myocardium was also increased from a mean of 227.1
± 13.9 to 259.2 ± 20.2 ms (p < 0.005) in this series of
patients.
The results indicate that long-term amiodarone
administration uniformly produces prolongation of His-
Purkinje system conduction time and refractoriness in
the human heart. .
riness of the His-Purkinje system in 24 patients receiving
long-term amiodarone therapy. The present electrophysio-
logic findings and their clinical implications are discussed
in this report.
Methods
Patients. The study group consisted of 24 consecutive
patients (16 men and 8 women) aged 31 to 75 years (mean
58.9 ± 11.4) who underwent complete electrophysiologic
studies before and II to 42 weeks (mean 16.2 ± 7.7) after
oral administration of amiodarone. Eighteen patients had
atherosclerotic heart disease, three had congestive cardio-
myopathy, two had mitral valve prolapse and the remaining
patient had no clinically detectable structural heart disease.
Electrophysiologic studies. These studies were con-
ducted with the patient in a postabsorptive nonsedated state.
The nature of the procedure was explained to all patients
and signed consent was obtained. During the control study,
no patient was taking cardioactive medication. Under local
anesthesia, multipolar electrode catheters were introduced
percutaneously into peripheral veins, and under fluoroscopic
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guidance were positioned into the regions of high right atrium,
AV junction and right ventricle for pacing or recording, or
both, with techniques previously described (II). Surface
electrocardiographic leads I, II and V2, intracardiac elec-
trograms and time lines were simultaneously displayed on
a multichannel oscilloscope and recorded on a magnetic tape
for later reproduction.
Electrical stimulation was performed using a digital stim-
ulator capable of delivering rectangular impulses with ad-
justable voltage and duration. During these studies, patients
were isolated and all equipment was grounded at equipo-
tential. In all patients, atrial and ventricular incremental
pacing and premature stimulation were completed according
to the protocols previously described. Retrograde refractory
period studies were performed using the ventricular extra-
stimulus method. At predetermined ventricular basic cycle
lengths (S I S I or VIVI)' progressively shorter SIS2(or VIV2)
intervals were introduced until the effective refractory pe-
riod of ventricular myocardium was reached. In patients
who had AV dissociation during the basic drive, the right
atrium and ventricle were paced simultaneously to avoid
interruption of basic cycle length from ventricular capture
by the sinus beats.
Definition of terms. Complete lists of definitions for
anterograde and retrograde conduction and refractory period
studies have been described previously (I I, I2). Only per-
tinent definitions related to this study are described here.
Anterograde studies. The HV interval was measured from
the onset of His bundle potential to the earliest detectable
ventricular activity measured on the surface electrocardio-
grams or any of the intracardiac electrograms.
Retrograde studies. During basic ventricular cycle length,
the retrograde His bundle deflections were not identifiable,
but during SIS2 (or VIV2) at closer coupling intervals, His
deflection emerged from the V2 electrogram. During ven-
tricular premature stimulation, the site of retrograde con-
duction delay or block, or both, (that is, the AV node versus
the His-Purkinje system) was determined by identifying the
retrograde His (H2) deflection by morphology and electro-
physiologic behavior (13). When doubt existed, the site of
retrograde block was confirmed by programming an atrial
extrastimulus after V2 and assessing the site of retrograde
concealed conduction (that is, the AV node versus His-
Purkinje system). The S2H2 (or V2H2) intervals were mea-
sured from the stimulus artifact to the onset of H2deflection.
It should be pointed out that in this report, the terms S2H2
and V2H2 are used interchangably.
Effective refractory period of the His-Purkinje system.
This was defined as the longest V1V2 interval where V2
blocks below the His bundle recording site.
Functional refractory period of the His-Purkinje system.
This was defined as the shortest S IH2 (or VIH2) interval in
response to a full range of SIS2 intervals. SIH2 (or VIH2)
was taken in lieu of retrograde H1H2 because retrograde HI
is generally not visible during basic drive but maintains a
constant relation with SI (I I ,14).
Effective refractory period of ventricular myocardium.
This was defined as the longest S1S2 interval at which S2
fails to depolarize the ventricle.
Reentry His-Purkinje system. The definition for reentry
His-Purkinje system has been published previously. Zone
of reentry His-Purkinje system was the range of V1V2 in-
tervals where V2 produced reentry His-Purkinje system
(11,15).
Oral amiodarone therapy. After control studies, all
patients received a loading dose of 1,200 to 1,600 mg/day
for I to 2 weeks and then continued on a maintenance dose
of 400 to 800 mg/day until the time of repeat electrophys-
iologic study (Table 1). The duration of therapy at time of
study ranged from II to 42 weeks (mean 16.2 ± 7.7) (Table
I) and the patients were not receiving any other antiar-
rhythmic agent at the time of repeat study.
Statistical analysis. Statistical significance of changes
in electrophysiologic variables after amiodarone was as-
sessed using Student's paired t test. Data are expressed as
mean values ± standard error of the mean.
Results
Relevant clinical data are summarized in Table I. All
patients were in sinus rhythm during both the control and-
postamiodarone studies. Atrioventricular (AV) conduction
was intact in all but one patient (Case 15) who had congenital
third degree AV nodal block with a junctional escape mech-
anism. Complete data concerning anterograde and retro-
grade conduction and refractory periods are available for all
of these cases. However, only data pertaining to His-Pur-
kinje system conduction and refractoriness will be reviewed
in detail here.
The effect of amiodarone on sinus cycle length, anter-
ograde AV nodal conduction and refractoriness and atrial
refractoriness was similar to that described previously (4,6,10).
In virtually all instances, these variables were prolonged.
Anterograde His-Purkinje system conduction (RV in-
tervals) (Table 2), In all but three patients (Cases 3,16 and
19), the HV interval showed a prolongation after admin-
istration of amiodarone. The mean value for the HV intervals
during the control period was 49.6 ± 9.5 ms (range 40 to
80) and increased to 60.6 ± 10.7 ms (range 45 to 90) after
amiodarone. The mean increase in the HV interval was 11.0
± 5.6 ms (p < 0.005). In 21 of24 patients, the HV intervals
were within the normal range (35 to 55 ms) during the
control period; in the remaining 3 patients (Cases 6, 12 and
19), these intervals were prolonged (60, 80 and 70 ms,
respectively). The magnitude of change after amiodarone
was the same regardless of the duration of the HV interval
during the control period.
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Table L Clinical Data
Amiodarone Therapy
Duration Before
Age (yr) Structural History of Surface Repeat Study Dosage (rng/day)
Case &Sex Heart Disease Arrhythmias Electrogram (wk) at Repeat Study
1 60M ASHD VT, VF SR, ant-sept MI 14 800
2 65F ASHD VT. VF SR. ant MI 16 800
3 70M Congestive cardiomyopathy VT SR, nonspecific 12 800
ST-T changes
4 75M ASHD VT SR. nonspecific 42 600
ST-T changes
5 31F MVP VT SR, nonspecific II 800
ST-T changes
6 61M ASHD VT. VF SR. inf MI, RBBB 12 800
7 65M ASHD VT SR, inf MI 28 600
8 56F Congestive cardiomyopathy VPC's VT SR, nonspecific 14 800
ST-T changes
9 67M ASHD VT SR, ant MI 13 800
10 46M ASHD VF SR, inf MI, LBBB IS 800
I I 58M None VF SR. nonspecific 13 800
ST-T changes
12 63M Congestive cardiomyopathy VT SR. nonspecific II 600
ST-T changes
13 66M ASHD VT SR, ant MI 15 600
14 34F MVP VT SR, nonspecific 12 800
ST-T changes
15 56M ASHD VT SR, inf MI II 600
16 56M ASHD VT SR, ant MI I I 600
17 54M ASHD VF SR. ant MI 17 400
18 58F ASHD VT. VF SR. inf MI 16 800
19 68M ASHD VT SR. ant MI 15 800
20 64F ASHD VT SR, ant MI I I 800
21 39F Coronary artery embolism VT SR. ant MI 34 800
and LVA resection
22 70M ASHD VT, VF SR. ant MI 10 600
23 60F ASHD VF SR. inf MI, LBBB 22 600
24 12M ASHD VT SR, ant MI 13 600
ant =, anterior; ASHD = arteriosclerotic heart disease; F = female; inf = inferior; LBBB = left bundle branch block; LV = left ventricle; LVA
= left ventricular aneurysm; MVP = mitral valve prolapse; M = male; RBBB = right bundle branch block; sept = septal; SR = sinus rhythm; VF
= ventricular fibrillation; VPC' s = ventricular premature complexes; VT = ventricular tachycardia.
Retrograde His-Purkinj e system conduction and re-
fr ac toriness (Table 2). The introduc tion of V2 was started
at a V\V2 interva l generally 100 to 150 ms shorter than the
basic ventricular cycle length (SIS2)' The longest V jV2 in-
terval that produced emergence of retrograde H2 from V2
was longer after amiodarone in 18 patients (Cases 1 to 16,
19 and 24, Table I , Fig. I and 2A); in the remaining 6
patients V2 encountered bilateral block below the His bun-
dle , that is, within the His-Purkinje system. In the 18 pa-
tients in whom V2 produced an Hz respo nse during both
studies, the mean value of the longes t V\V2 interva ls at H2
emergence was 318.8 ± 33.1 ms before and 376.4 ± 46.6
ms after amiodarone (p < 0 .005). The mean increase in
V\V2 ".t the point of H2 emergence ranged from 10 to 130
ms at the basic ventricular cycle length tested . At the longest
V\V2interval, no significant stimulus to ventricular response
latency was observed aftet S2 as compared with S I on any
intracardiac elec trogram recorded before or after drug
admi nistration.
The V2H2 delays were also compared in all patients in
whom the two values were available before and after amio-
darone. Table 2 shows that at the same V\V 2 intervals, the
shortest and the longest V2H2 delays were consistently longer
in virtually all patients. At the longest V2H2 delays , the
corresponding coupling intervals were short and generally
accompanied by stimulus to ventricu lar response latency
both before and after drug administration . However, at these
short (and long) V I V2 intervals , the V2H2 interval after
amiodarone consistently exceeded control values when this
interval was measured from the end of the local V2 elec-
trogram (or QRS comp lex) (compare Fig. I and 2). This
observation suggests that intramyocardial delay did not sig-
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Table 2. Electrophysiologic Data
Case
HV
Interval
VCL
C AM (S,Stl
Longest
S,Sz at
Which Hz
Emerged
C AM
At Longest At Shortest FRP-HPS
Comparable*Comparable* (shortest
S,S2 S,Sz V,Hz)
C AM C AM C AM C AM
Critical
S2HZ
for Re-HPS
C AM
ERP-VM
C AM
I
2
3
4
5
6
7
8
9
10
II
12
13
14
15
16
17
18
19
20
21
22
23
24
40 60
40 55
55 55
50 60
45 50
80 90
50 60
55 65
50 65
45 55
45 55
60 70
40 45
55 80
45t 60t
55 55
45 55
70 80
45 45
45 60
45 70
45 50
45 65
40 50
600
600
600
600
600
600
600
600
600
600
600
600
500
600
600
700
600
600
600
600
600
600
600
600
330 350
320 400
340 360
300 320
320 360
360 400
280 310
260 280
340 470
360 380
320 400
300 340
240 350
300 420
320 420
350 400
320 BBH
280 BBH
360 370
280 BBH
320 BBH
320 BBH
320 BBH
340 440
160 180 210 240 490 530
170 220 240 280 490 620
180 210 290 330 520 570
135 155 200 220 430 475
170 190 260 280 490 550
130 180 130 235 490 555
190 225 210 260 470 520
155 270 210 310 415 550
120 190 175 220 460 560
150 180 210 330 510 540
130 150 270 310 450 550
200 225 250 265 500 565
210 230 220 280 430 560
130 230 210 380 450 630
230 280 260 440 550 700
140 190 220 260 490 590
160 BBH 260 BBH 480 BBH
200 BBH 250 BBH 480 BBH
140 170 200 BBH 500 530
170 BBH 230 BBH 550 BBH
200 BBH 280 BBH 520 BBH
160 BBH 310 BBH 480 BBH
170 BBH 300 BBH 490 BBH
200 290 280 BBH 520 610
320-280
240-210
270
320-260
320-160
320-260
280-280
300-250
320-280
250
400-340
400-320
210-220
240-300
220
230-260
180-210
160-260
230-250
210-200
200-230
380
370-440
200-245
75-80
60-90
70
70
70-80
60-75
65-70
60
70
240 250
220 290
260 290
230 250
220 250
230 250
200 240
230 290
240 280
210 240
220 240
240 280
200 220
110 220 240
120 250 280
90 240 260
230 260
240 290
220 240
220 240
220 280
230 250
220 260
220 250
All values are in milliseconds. *Comparable implies the same S,Sz; tduring junctional escape rhythm. AM = amiodarone; BBH = blocked below
His; C = control; ERP = effective refractory period; FRP = functional refractory period; HPS = His-Purkinje system; Re-HPS = reentry in His-
Purkinje system; VCL = ventricular cycle length; VM = ventricular myocardium.
nificantly contribute to prolongation of VzHz intervals after
administration of amiodarone. The shortest available V1Hz
intervals were also consistently longer after amiodarone
administration.
Nine patients (Cases 12 to 20, Table 2) demonstrated the
phenomenon of macroreentry in the His-Purkinje system
during the control study. In four of these nine (Cases 17 to
20), reentry in the His-Purkinje system did not occur after
amiodarone administration because of persistent retrograde
block in the His-Purkinje system, whereas in two of nine
(Cases 12 and 13), reentry in the His-Purkinje system was
abolished even though the VzHz delays were longer after
amiodarone than in the control period. In only three of the
nine (Cases 14 to 16) was reentry in the His-Purkinje system
noted during the repeat study. Reentry in the His-Purkinje
system in two of the latter three cases appeared at longer
V I Vzintervals after amiodarone administration as compared
with that in the control period. In the zone of reentry in the
His-Purkinje system, the VzHz and HzV3 intervals were also
longer during the repeat study on amiodarone. In all in-
stances, the reentry in the His-Purkinje system was in the
form of a single beat (V3) which terminated with retrograde
block in the His-Purkinje system (that is, no H3) .
Refractoriness of the ventricular myocardium. The
effective refractory period of the ventricular myocardium
was prolonged in all patients (mean 227.1 ± 13.9 ms [range
200 to 260] before and 259.2 ± 20.2 ms [range 240 to 290]
after amiodarone).
Discussion
Effect of amiodarone on His-Purkinje system. Our
results show that amiodarone prolongs the conduction time
and refractoriness of the His-Purkinje system in the human
heart. Even the three patients without prolongation of the
HV interval manifested lengthening of other variables of
His-Purkinje system refractoriness. It is not completely clear
why the HV interval was not prolonged in these cases. It
may, in part, be related to the possibility that the recordings
during the repeat study were obtained from a more distal
location. This could have counterbalanced a small degree
of prolongation in the His-Purkinje system conduction time
JACC Vol. I. No. I
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A BC L : 60 0 rns Ca nt r o l
Figure 1. Case 14. His-Purkinje sys- 2
tern conduction refractoriness in the
control period before amiodarone. A,
The atria (closed arrows) and ventri- 150
cles (open arrows) are being paced t.... ~ f'
simultaneously during the basic drive. v H V;.~ .. A •At a basic cycle length (BCL) of 600 SIS? 300 Il ~ms and an S,S2 interval of 300 ms, the H B
S2H2 interval (retrograde His-Purkinje s, sf" S?H? 150 8H?A2 '85 I 55"
system conduction time) measures 150
ms. B, The longest S2H2 intervals ob- B
500 ms
, , ,
tained in this patient before the effec-
tive refractory period of ventricular
myocardium was encountered at an S,S2
interval of 220 ms. The duration of
sinus cycle length, AH and HV inter- I I~ rw--~r . ivals during the control period are la- v?
beled in 1\. HB = His bundle elec- A 2
,oJ I. IWI)trogram; RA = right atrial electrogram; 112 il- 5 ,52 230 ....2 = surface electrocardiographic lead s, 52 I 52 112 225 I ~ ,II. H2A 2 18 5
after amiodarone administration. Published data (4,6,10)
concerning the effect of amiodarone on the His-Purkinje
system are rather limited and have not shown a consistent
prolongation in His-Purkinje system conduction time of the
magnitude seen here. Some of the discrepancy between our
results and previous data suggesting insignificant effects on
His-Purkinje system conduction may be due to the longer
duration of treatment and higher average dose used in our
study compared with those in earlier reports. To date, a
systematic appraisal of the effect of amiodarone on His-
Purkinje system refractoriness in the human heart has not
been reported.
Effect of amiodarone on ventricular myocardium.
Amiodarone lengthened the effective refractory period of
ventricular myocardium in our study as in those of others
(4,6,10). Because refractoriness of the ventricular myocar-
dium was increased after administration of the drug, one
can argue whether the prolongation of V2H2 intervals was
A BC L: 6 0 0 ms Po st Amio d a ro ne
Figure 2. Case 14. His-Purkinje sys-
tem conduction and refractoriness after
amiodarone. At the same basic cycle
length as in Figure I, the S2H2 interval
is significantly longer than in panel A
of Figure I (250 versus 150 ms) de-
spite a much longer SIS2 interval (420
versus 300 ms). The longest available
S2H2 delays seen in panel B of both
figures were also significantly longer
after amiodarone. Even though the QRS
complex of paced V2 is wider after
arniodarone (as compared with the
control study in Figure I), the V2H2
intervals are significantly longer after
amiodarone therapy even when the
measurement is made from the end of
the V2electrogram. Panel A also shows
the sinus cycle length, AH and HV
intervals. which are prolonged after
arniodan me as compared with the con-
trol period (panel A of Fig. 1).
A
A)935
~/ Jr-
I v v
A H A H
5,52.420 !I--
S2H2 , 25 0 1 0I 80
B 500 ms
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secondary to intramyocardial rather than His-Purkinje sys-
tem conduction delays. This possibility cannot be excluded
at shorter coupling intervals associated with stimulus to
ventricular myocardium response latency. However, a uni-
form increase in VzHz delays at the longest coupling inter-
vals where no such intramyocardial delays were noted after
amiodarone suggests a direct depressant effect of this study
on the His-Purkinje system. The occurrence of persistent
bilateral block within the His-Purkinje system (that is, V2
but no Hz) in 6 of 24 patients also supports the drug's
depressant effect on the His-Purkinje system.
Effect of amiodarone on reentry in the His-Purkinje
system. Macroreentry in the His-Purkinje system was abol-
ished in six of nine patients in whom the phenomenon was
noted during the control period. In four of the six, persistent
retrograde bilateral block in the His-Purkinje system ac-
counted for this effect, whereas in two patients (Cases 12
and 13), abolition of reentry in the His-Purkinje system
despite longer available VzHz delays suggests that prolon-
gation of the refractoriness in the right bundle branch produced
this effect. In the three cases where reentry in the His-
Purkinje system was noted before and after amiodarone
administration, the V3 was associated with significantly longer
VzHz and HzV3 intervals during repeat study. These findings
indicate that after Vz, a prolonged recovery time was needed
for the right bundle branch to allow propagation of the Hz
impulse in the presence of amiodarone.
Implications. The exact role of the peripheral Purkinje
system in the reentrant circuit of ventricular tachycardia in
human beings is not completely known at the present time.
For example, it is not clear whether ventricular tachycardia
circuits are entirely localized within ventricular myocardium
or whether the adjacent Purkinje fibers are an essential part
of the circuit (16-18). Because amiodarone exerts a de-
pressant effect on the normal and abnormal His-Purkinje
system and on ventricular myocardium, the drug will be
expected to be efficacious in a wide variety of ventricular
tachyarrhythmias. The clinical experience with amiodarone
thus far attests to its potency in controlling ventricular tach-
yarrhythmias (5-8, 10). Even though amiodarone efficacy
in controlling ventricular tachyarrhythmias may not nec-
essarily be due to drug-induced prolongation of conduction
and refractoriness of the His-Purkinje system or ventricular
myocardium, or both, the latter remains a likely mechanism.
We thank Ann Edwards and Brian Miller for their assistance in the prep-
aration of this manuscript.
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